metformin has been researched along with Gigantism in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Gigantism: The condition of accelerated and excessive GROWTH in children or adolescents who are exposed to excess HUMAN GROWTH HORMONE before the closure of EPIPHYSES. It is usually caused by somatotroph hyperplasia or a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. These patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
García-Beltran, C | 1 |
Cereijo, R | 1 |
Quesada-López, T | 1 |
Malpique, R | 1 |
López-Bermejo, A | 1 |
de Zegher, F | 1 |
Ibáñez, L | 1 |
Villarroya, F | 1 |
Kuo, SF | 1 |
Chuang, WY | 1 |
Ng, S | 1 |
Chen, CH | 1 |
Chang, CN | 1 |
Chou, CH | 1 |
Weng, WC | 1 |
Yeh, CH | 1 |
Lin, JD | 1 |
Ali, O | 1 |
Banerjee, S | 1 |
Kelly, DF | 1 |
Lee, PD | 1 |
1 trial available for metformin and Gigantism
Article | Year |
---|---|
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo | 2020 |
2 other studies available for metformin and Gigantism
Article | Year |
---|---|
Pituitary gigantism presenting with depressive mood disorder and diabetic ketoacidosis in an Asian adolescent.
Topics: Adenoma; Adolescent; Adolescent Development; Antineoplastic Agents, Hormonal; Combined Modality Ther | 2013 |
Management of type 2 diabetes mellitus associated with pituitary gigantism.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diabetes Mellitu | 2007 |